Comparini B, Maldonado GB, Musé IM, Navarro CJ, Neira RLF, Sierra SI

Language: Spanish
References: 7
Page: 6-9
PDF size: 57.43 Kb.

ABSTRACT

An important Latin American meeting of Oncology experts was carried out in Miami, Florida, with the participation of oncologists from several countries in the region (Mexico, Brazil, Colombia, Argentina, Uruguay, Chile, etc.). This consensus meeting had the aim of sharing the current knowledge this clinicians and researchers have about different type of neoplasia and their updated clinical management according to the latest criteria and guidelines developed by the main research sites around the world, in order to present a useful document for these specialists in their daily work with cancer patients. With the aim of exploring and discussing six different important oncological topics and establish some useful guidelines, participants were divided in six working groups with the following themes: 1) guidelines for the management of bone loss secondary to cancer treatment; 2) guidelines for the management of hormone dependent breast cancer; 3) guidelines for the management of bone metastases in lung cancer patients with zoledronic acid; 4) guidelines for the management of bone metastases secondary to breast cancer with zoledronic acid; 5) guidelines for the management of breast cancer with extended adjuvant therapy, and 6) guidelines for the management of GIST (gastrointestinal stromal tumors). This document presents the analysis of the GIST, including the conclusions attained by the participants. GIST are mesenchymal neoplasia of the GI (gastrointestinal) tract with clinical features that were not understood for a long time, until a couple of decades ago, when the knowledge about its particular etiology began to be discovered They are defined as the stromal tumors located at any region of the tract from the esophagus to the rectum. Morphologically, GIST resembles other soft tissue benign and malign tumors and the so called neural stromal neoplasia, but they belong to a totally different group of GI tumors originated in the Cajal cells.

REFERENCES

1. Logroño R, Jones DV, et al. Recent advances in cell biology, diagnosis and therapy of gastrointestinal stromal tumor (GIST). Cancer Biol Ther, 2004 Mar; 3 (3) [Epub ahead of print].

2. Maki RG. Gastrointestinal Stromal Tumors Respond to Tyrosine Kinase targeted Therapy. Curr Treat Options Gastroenterol, 2004 Feb; 7(1):13-17.

3. Eisenberg BL. Imatinib mesylate: a molecularly targeted therapy for GIST. Oncology (Huntingt), 2003, Nov; 17(11):1615-20.

4. Debiec-Rychter M, Dumez H, et al. Use of c-KITPDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J cancer 2004 Mar;40(5):689-95.

5. Gunhild M, Gerlinde E, et al. Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch 2004 444:108-118.

6. P Reichardt, U. Schneider, C Stroszcynski, et al. Molecular response og gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate. J Clin Pathol 20004;57:215-17 (Case Report).

7. Bechtold RE, Chen MY, et al. Cystic changes in hepatic and peritoneal metastases from GIST treated with Gleevec. Abdom Imaging 2003 Nov-Dec;28(6):808-14.